Header cover image

South Korean (KOSPI) Pharma Industry Analysis

UpdatedJul 01, 2022
DataAggregated Company Financials
Companies96
  • 7D1.7%
  • 3M-16.0%
  • 1Y-39.7%
  • YTD-23.3%

The Pharma industry is up 5.8% in the last week, with SK Biopharmaceuticals up 6.8%. However, the industry is down 39% over the past year. Earnings are forecast to grow by 41% annually.

Industry Valuation and Performance

Has the South Korean Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Sat, 02 Jul 2022₩47.6t₩26.7t₩475.9b20.7x
Mon, 30 May 2022₩53.5t₩26.6t₩555.9b23.8x
Wed, 27 Apr 2022₩56.1t₩26.1t₩674.3b28.3x
Fri, 25 Mar 2022₩56.5t₩25.7t₩705.9b24.4x
Sun, 20 Feb 2022₩52.7t₩25.0t₩934.5b23x
Tue, 18 Jan 2022₩55.4t₩25.0t₩934.5b23.1x
Thu, 16 Dec 2021₩62.0t₩25.0t₩934.5b26x
Sat, 13 Nov 2021₩59.7t₩24.7t₩875.4b23.6x
Mon, 11 Oct 2021₩62.4t₩24.7t₩876.1b23.7x
Wed, 08 Sep 2021₩72.1t₩26.0t₩960.6b38.7x
Fri, 06 Aug 2021₩72.1t₩25.3t₩928.3b41.5x
Mon, 10 May 2021₩69.3t₩24.9t₩915.5b34.8x
Sun, 31 Jan 2021₩76.0t₩24.6t₩897.5b35.5x
Wed, 04 Nov 2020₩68.8t₩24.4t₩499.4b27.5x
Sat, 08 Aug 2020₩69.8t₩24.0t₩524.2b27.7x
Fri, 01 May 2020₩40.3t₩23.6t₩732.3b21.1x
Mon, 03 Feb 2020₩37.2t₩23.1t₩621.5b26.6x
Thu, 07 Nov 2019₩39.4t₩21.8t₩547.5b24.5x
Wed, 31 Jul 2019₩37.1t₩21.1t₩625.0b23.4x
Median PE Ratio

25.9x


Total Market Cap: ₩42.3tTotal Earnings: ₩625.0bTotal Revenue: ₩21.1tTotal Market Cap vs Earnings and Revenue0%0%0%
South Korean Pharma Industry Median PE3Y Average 27.8x202020212022
Current Industry PE
  • Investors are optimistic on the industry, and appear confident in long-term growth rates.
  • The industry is trading at a PE ratio of 99x which is higher than its 3-year average PE of 81.2x.
  • The industry's 3-year average PS ratio 2.4x is higher than the industry's current PS ratio of 1.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 8.7% per year over the last three years.
  • Meanwhile revenues for these companies have grown 8.2% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does South Korean Pharma compare with similar industries?

KR Market-1.34%
Healthcare-1.07%
Pharma1.73%
Pharma1.73%
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
A069620 Daewoong pharmaceuticalLtd₩173.00k6.5%
+₩116.2b
0.3%PE31.2x
A039200 Oscotec₩26.90k7.4%
+₩58.3b
-34.9%PS209.8x
A003090 Daewoong₩26.95k5.5%
+₩58.2b
-41.7%PE11.3x
A068760 Celltrion Pharm₩78.50k1.8%
+₩52.6b
-50.3%PE113.4x
A004310 Hyundai Pharmaceutical₩5.73k43.8%
+₩48.1b
-20.3%n/a
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News